In Q2 2026, Tang Capital Management held 35 positions worth $2.0B. They initiated 4 new positions and exited 196. Their largest holding was AUPH ($221.4M). Portfolio value grew +13.3% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q2 2026?
Tang Capital Management held 35 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include AUPH, SYRE, MIRM, KNSA, CELC. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q2 2026?
Tang Capital Management's tracked biotech portfolio was worth $2.0B across 35 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q2 2026?
Tang Capital Management initiated 4 new positions in Q2 2026, including NVCT, FULC, NNDM, BOLD. They also increased 6 existing positions.
What did Tang Capital Management sell in Q2 2026?
Tang Capital Management fully exited 196 positions in Q2 2026, including LONA, PCRX, ALGS, ENTA, INBX and 191 more. They also trimmed 4 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Managementportfolio →